Skip to Content

Tag: Apnimed


Also Noted

Apnimed treatment shows reduction in AHI

November 17, 2021HME News Staff

CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has announced positive topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, three-period crossover study (protocol APX-001) in patients with OSA evaluating AD504 and AD182. Patients treated with AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in AHI from placebo, which...

Apnimed, Sleep Apnea


Read Full Articlered right arrow icon